Dean Li invites another under-the-radar biotech to Merck's dealmaking table as Amathus signs neurodegeneration pact

Less than three months since taking over from Roger Perlmutter, new Merck R&D chief Dean Li continues to wheel and deal.

Li and the …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Dean Li in­vites an­oth­er un­der-the-radar biotech to Mer­ck­'s deal­mak­ing ta­ble as Am­ath­us signs neu­rode­gen­er­a­tion pact